Peptide Dosing & Reconstitution Reference: The Math Behind the Vial

This is an informational and editorial reference for reading comprehension and source transparency only. It is not medical advice, not a prescription, not a protocol to follow, and not a sourcing or buying guide. Reconstituting and injecting peptides is a clinical act that should occur only under a qualified, licensed clinician's supervision, using products of verified pharmaceutical quality. Many peptides discussed are not FDA-approved, several are prohibited in sport, and most "research peptides" sold online are labeled not for human use. All doses are stated strictly as seen in the literature or clinical use. Always consult a licensed clinician; never self-administer based on this document.

What are the three classes of a peptide "dose"?

The most common error in peptide writing is treating a number as authoritative because it is widely repeated. Every dose in the peptide space belongs to one of three classes, and they must never be presented as equivalent. The functional-medicine instinct applies here too: fix the upstream driver of a complaint before reaching for an injectable, and reserve injectables for clinician-supervised use.

Tier 1 — FDA-approved peptides are the only ones whose doses are both precise and trial-validated: semaglutide (Wegovy) titrates over 16 weeks to a 2.4 mg once-weekly maintenance dose, producing roughly 12-13 percent weight loss at 68 weeks (Grade A).2 Teriparatide (Forteo) is a fixed 20 mcg once daily with no titration; the Neer trial cut new vertebral fractures 65 percent.3 Bremelanotide (Vyleesi) is 1.75 mg as needed, with frequency caps that are explicitly safety limits, not efficacy ceilings.4

Tier 2 — unapproved peptides with real trial doses exist but are studied in small, early, or failed trials. MK-677 (ibutamoren) was dosed at 25 mg/day orally in a 2-year Annals of Internal Medicine RCT that restored IGF-1 into the young-adult range but also raised fasting glucose and insulin (Grade B).5 The dose is real; the efficacy is preliminary at best.

Tier 3 — popular "research peptides" with no established human dosing include BPC-157, TB-500, CJC-1295 and epitalon. Every circulating number is a rodent extrapolation or a figure copied between forums, and no efficacy claim is supportable.6 When a peptide lacks human trials, the honest statement is "no established human clinical dose" rather than a precise-sounding but untested figure.

How does peptide reconstitution math actually work?

Reconstitution is dissolving a freeze-dried powder into a sterile liquid so it can be measured and injected. The entire arithmetic reduces to two operations the user controls, performed in a fixed order.7

1. Concentration (mg/mL) = total peptide mass in vial (mg) / volume of diluent added (mL). The powder mass is fixed; the concentration is set entirely by how much water you inject. This is the single most important conceptual point — two users of identical vials get different "units per dose" purely from picking different diluent volumes.
2. Draw volume (mL) = target dose / concentration. This only works if dose and concentration share units. Because vials are labeled in mg but doses are often quoted in mcg, apply 1 mg = 1,000 mcg before dividing, or the answer is off by 1,000-fold.

Insulin syringes read in units, not mL, with the conversion built into the barrel. For a U-100 syringe, 1 mL = 100 units, so 0.1 mL = 10 units and 0.5 mL = 50 units. Compute draw volume in mL, then multiply by 100.15 The reference calculators that circulate online, such as the Rite Aid peptide dosage calculator, perform this arithmetic correctly but, by their own disclaimers, do not set a dose or confirm appropriateness.16

Concentration mismatch is multiplicative, not additive. A U-100 syringe assumes 100 units/mL; drawing a 5x-more-concentrated solution to the "20-unit" mark delivers five times the intended dose — which is exactly why a units number is meaningless unless the reconstitution ratio is stated and matched to a correctly calibrated syringe.15

Why does the route of administration change the dose?

A dose only makes sense alongside a route, because peptide bioavailability spans under 1 percent to nearly 100 percent depending on how the molecule enters the body.13 This is why injection dominates: of 70-plus approved peptide drugs, about 78 percent are parenteral (subcutaneous ~36 percent, IV ~26 percent, IM ~14 percent).12 Subcutaneous injection yields roughly 75-100 percent bioavailability and is the default that label and trial doses assume unless stated otherwise. Oral peptides are typically under 1-2 percent bioavailable — oral semaglutide (Rybelsus) co-formulates the drug with roughly 300-400 mg of the SNAC absorption enhancer and still achieves only about 1 percent bioavailability, salvaged solely by semaglutide's high potency and 7-day half-life.14 The codified rule follows directly: never port a dose across routes. An FDA-approved subcutaneous drug does not validate a compounded oral or nasal version of the same peptide — bioavailability and safety must be re-established per route.

What diluent should a multi-dose vial use?

The diluent choice is the single biggest handling decision after the math. Bacteriostatic Water for Injection, USP is sterile water containing 0.9 percent (9 mg/mL) benzyl alcohol as a preservative, supplied in a multiple-dose container; the preservative suppresses microbial growth between punctures, supporting multi-dose use.9 Sterile Water for Injection, USP has no preservative, so a vial reconstituted with it is effectively single-use.17 Benzyl alcohol carries real safety boundaries documented in FDA labeling: it is associated with the neonatal "gasping syndrome" above 99 mg/kg/day, is not for epidural or spinal use, and is contraindicated in benzyl-alcohol hypersensitivity — only preservative-free sterile water should be used for neonatal preparations.18 Some poorly soluble peptides that go cloudy in bacteriostatic water are instead dissolved in dilute acetic acid to drop pH, since most degradation pathways are minimized around pH 3-5 (the pH-stability mechanism is well established; the per-peptide diluent picks are vendor practice).19

How should reconstituted peptides be stored?

The anchoring truth is that lyophilized powder is chemically quiet because removing water suppresses degradation; the moment water is added, almost every decay route — deamidation, oxidation, backbone hydrolysis, aggregation, disulfide scrambling — switches back on, collapsing usable life from months or years to days or weeks.19 Store the dry powder cold, dark and dry, and bring it to room temperature sealed before opening so moisture does not condense onto the cake. Add water to the vial wall, not the cake, and swirl gently — never shake or vortex, because mechanical shear and air-liquid interfaces drive aggregation. Refrigerate the reconstituted vial at 2-8 degrees Celsius, protect it from light, and do not freeze it: freeze-thaw of an aqueous peptide causes irreversible, potentially immunogenic aggregation, so you freeze the dry powder, not the solution.21

What does 2026 US regulation say about peptide doses?

A quoted dose is not a legal or approved dose, and the US picture changed materially in 2025-2026. In September 2023 the FDA placed a dozen-plus peptides, including BPC-157, into 503A Category 2 ("significant safety risk — do not compound").11 In April 2026 the FDA removed several peptides (BPC-157, TB-500, CJC-1295 and others) from Category 2 — but did not move them to Category 1 (permitted); removal from Category 2 is not approval.26 A Pharmacy Compounding Advisory Committee hearing is scheduled for July 23-24, 2026 to weigh several peptides for the 503A Bulks List, and the public docket accepted comments through July 22, 2026; you can read the meeting notice on the FDA advisory-committee calendar.10 As of this writing the meeting had not yet occurred, no vote exists, PCAC recommendations are non-binding, and a final FDA rule typically follows 6-18 months later. Separately, most "research peptides" carry a "research only / not for human use" label — a quality gap that cannot be restored downstream by good handling.11

Where does harm actually enter — and what are the codified rules?

The arithmetic is trivial; the errors are not. The FDA's 2024 compounding alert attributed reported overdoses to unit confusion and to providers miscalculating doses when converting milligrams to units or milliliters, producing 5-to-10-fold overdoses of compounded semaglutide — including one case where a provider meant 0.25 mg (5 units) and instead specified 25 units.8 Titration exists to prevent a different harm: skipping the GLP-1 ramp predictably causes severe nausea, and a 2025 case report documented a patient who restarted semaglutide at 2 mg without re-titration and progressed to dehydration-driven acute kidney injury.23 Cycling, by contrast, is over-generalized: desensitization is real and human-documented for GHS-R1a agonists like hexarelin, but the GHRH analog tesamorelin maintained full efficacy across 52 weeks of uninterrupted daily dosing.2425 And duration is dictated by pharmacology — STEP 4 showed nearly 7 percent weight regain on placebo, confirming GLP-1s are chronic-continuous drugs.22

The codified rules for reading any peptide dose: separate the three dose classes and never present a community dose as trial-validated; attach an evidence grade to every dose-linked efficacy claim; cite the dose to its primary source; state units and frequency and route every time; flag formulation-specific dosing; compute concentration first, then draw volume, then units, always stating the reconstitution ratio; convert mg to mcg before dividing; match the syringe calibration to the actual concentration; treat the 28-day beyond-use date as a ceiling; never freeze a reconstituted vial; date-check all regulatory facts to the current year; and carry the not-medical-advice, not-a-sourcing-guide disclaimer wherever doses appear.27

Bottom line. The peptide-dosing space rewards precision about what kind of number you are holding. An FDA-label dose, a human-trial dose, and a forum figure are not interchangeable; the reconstitution math is trivial but the unit errors are lethal; and the diluent, storage and regulatory facts are all product-specific and date-sensitive. Regulatory facts here are current as of June 2026; the July 23-24, 2026 PCAC outcome was pending at the time of writing and should be re-verified after that date.